Advanced Diffusion Imaging for Management of Renal Cancer: Oncologic Control and Renal Functional Reserve - Resubmission - 1

NIH RePORTER · NIH · R01 · $575,634 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY Renal cancer is a source of severe mortality and morbidity, not only due to the primary malignancy but also due to loss of renal function (sometimes leading to chronic kidney disease) after partial nephrectomy. Methods to noninvasively monitor renal function and predict its robustness against this decline of function are therefore in high demand. Diffusion-weighted MRI is well poised to play this role as an adjunct to renal cancer patients' existing clinical MR workup. Our group has been at the forefront of research into advanced renal diffusion MRI contrast, including methods to separate microstructure from microcirculation (intravoxel incoherent motion (IVIM)) and assess microscopic anisotropy (diffusion tensor imaging (DTI)). A recent comprehensive approach (REFMAP) collects these contrasts jointly, allowing assessment of microstructural and microcirculation anisotropy. We propose to apply this composite dataset both to classify aggressiveness of the primary renal lesion and to assess and predict post-surgical renal function. IVIM-MRI will be performed to characterize the aggressiveness of the primary lesion. The REFMAP-MRI protocol will be used to evaluate renal cancer patients before surgery and at 1 year follow up, in comparison with standard clinical workup (measured glomerular filtration rate, proteinuria). Cross-sectional correlation will validate the markers of the REFMAP-MRI technique as probes of renal function, and those baseline values predicting which patients experience renal function decline will be identified.

Key facts

NIH application ID
10051642
Project number
1R01CA245671-01A1
Recipient
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Principal Investigator
Hersh Chandarana
Activity code
R01
Funding institute
NIH
Fiscal year
2020
Award amount
$575,634
Award type
1
Project period
2020-08-01 → 2025-04-30